Ocumension Therapeutics announced that one of the Group's key drug candidates, OT-301, a first-in-class, nitric oxide (NO)-donating prostaglandin analog under joint development by Nicox S.A. and the company, has recently obtained an approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for initiating its second phase III clinical trial, namely the Denali trial, in China. The first phase III clinical trial of NCX 470, namely the Mont Blanc trial, has been initiated by Nicox in the United States in June 2020, in which the 0.1% dose was selected over the 0.65% dose through an adaptive design. The 0.065% dose of NCX 470 was the highest dose tested in the phase II clinical trial, namely the Glaucoma Dolomites trial, where demonstrated a superior intraocular pressure lowering treatment effect compared with latanoprost 0.005%, the most widely prescribed first-line therapy for glaucoma and ocular hypertension in China. The Denali trial is a three-month phase III multi-regional clinical trial evaluating the safety and efficacy of OT-301(NCX 470) ophthalmic solution, 0.1%, versus the current standard of care, latanoprost ophthalmic solution, 0.005%, for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The Denali trial, which will also include a long-term safety extension, is expected to randomize approximately 670 patients, at approximately 50 clinical sites in the United States and China. As of the date of this announcement, the Denali trial has been initiated in the United States by Nicox with the first patient enrolled on November 9, 2020.